Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Epigenetics (R)evolution

This article was originally published in Start Up

Executive Summary

Constellation and EpiZyme are poised to become dominant players in the unfolding field of epigenetics, an area of biology replete with novel, interesting targets and broad therapeutic potential. The two companies have adopted similar and until now stealthy strategies, aimed at parlaying a platform of novel products into a quick and lucrative exit.

Related Content

Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal
A Groundswell In Epigenetics
Constellation Brings In Series B Totaling $22 Million, Including GSK Investment
Biopharma Quarterly Statistics Q1 2010
Reversible Drug Resistance in Tumor Cells
Gloucester Pharma Snags $29 Million Series D
Financings Of The Fortnight: Follow-On Fever
iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform
Sirtris Satisfies GSK's M&A Appetite
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts